CN117229381A - Recombinant ginseng hypoglycemic peptide and preparation method and application thereof - Google Patents
Recombinant ginseng hypoglycemic peptide and preparation method and application thereof Download PDFInfo
- Publication number
- CN117229381A CN117229381A CN202311311882.9A CN202311311882A CN117229381A CN 117229381 A CN117229381 A CN 117229381A CN 202311311882 A CN202311311882 A CN 202311311882A CN 117229381 A CN117229381 A CN 117229381A
- Authority
- CN
- China
- Prior art keywords
- recombinant
- hypoglycemic peptide
- ginseng
- ginseng hypoglycemic
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 82
- 241000208340 Araliaceae Species 0.000 title claims abstract description 69
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 69
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 69
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 69
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 14
- 241000588724 Escherichia coli Species 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 206010022489 Insulin Resistance Diseases 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 238000001641 gel filtration chromatography Methods 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 3
- 241000235058 Komagataella pastoris Species 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 238000005185 salting out Methods 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 238000000855 fermentation Methods 0.000 abstract description 3
- 230000004151 fermentation Effects 0.000 abstract description 3
- 230000000593 degrading effect Effects 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960001931 ampicillin sodium Drugs 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The application discloses a recombinant ginseng hypoglycemic peptide, a preparation method and application thereof, wherein the recombinant ginseng hypoglycemic peptide is formed by repeating a short amino acid sequence of a natural ginseng hypoglycemic peptide as a repeating unit; the short amino acid sequence is ETVEIIDSEGGGDA, and the repetition number is 2-15. The recombinant ginseng hypoglycemic peptide of the application is prepared by repeating the natural ginseng hypoglycemic peptide for a certain times and then carrying out fermentation expression, thus being capable of effectively relieving the problem of degrading short peptide and remarkably improving the yield, and the prepared recombinant ginseng hypoglycemic peptide is capable of effectively reducing blood sugar.
Description
Technical Field
The application belongs to the technical field of genetic engineering, and particularly relates to a recombinant ginseng hypoglycemic peptide, and a preparation method and application thereof.
Background
Diabetes is called a health killer and poses a great threat to human health. At present, diabetes mellitus can only be relieved by hypoglycemic drugs, and has serious drug dependence. The long-term hyperglycemia of diabetics can cause a series of complications and even loss of life. Of the people older than 18 years in our country, type II diabetics have about 11.2%. In the diabetic population, type II diabetics can account for over 90%. Clinically, drugs such as insulins, insulinotropic agents, glucosidase inhibitors, insulin sensitizers and the like are commonly used for treatment.
The peptide hypoglycemic agent has obvious advantages, and provides a new direction and a new thought for the research and development of hypoglycemic agents in the future. Firstly, peptides are mostly endogenous peptides or other natural peptides, the structure is clear, and the action mechanism is clear; secondly, compared with the general micromolecular medicaments, the polypeptide medicaments have higher activity, smaller medicament dosage and lower toxic and side effects, and the metabolic products are amino acids; thirdly, compared with protein, the peptide has little immunogenicity, can be chemically synthesized, and has high purity and controllable quality; fourth, peptides tend to circumvent gastrointestinal digestion, overcoming the disadvantage of protein molecules being destroyed by digestive enzymes and thus not being orally available.
The existing hypoglycemic drugs are easy to be degraded by digestive enzymes after being orally taken, and the use cost is high; and the short amino acid sequence is easy to degrade, denature and the like. If the composition and distribution of the short amino acids are increased repeatedly, the degradation of the short amino acids can be effectively relieved, so that the stability and the drug effect of the short amino acids are improved.
Disclosure of Invention
The application aims to solve the technical problems of the prior art and provides a recombinant ginseng hypoglycemic peptide and a preparation method and application thereof. The recombinant ginseng hypoglycemic peptide of the application is obtained by repeating the natural ginseng hypoglycemic peptide for a certain times and then carrying out fermentation expression, thus being capable of effectively relieving the problem of degrading short peptide and remarkably improving the yield, and the recombinant ginseng hypoglycemic peptide is capable of effectively reducing blood sugar.
In order to solve the technical problems, the application adopts the following technical scheme: a recombinant ginseng hypoglycemic peptide is characterized by being formed by repeating a short amino acid sequence of a natural ginseng hypoglycemic peptide as a repeating unit; the short amino acid sequence is ETVEIIDSEGGGDA (SEQ ID NO: 1), and the repetition number is 2-15.
In addition, the application also provides a gene for encoding the recombinant ginseng hypoglycemic peptide.
Further, the present application provides an expression vector containing the above gene.
Further, the present application provides a host cell containing the above expression vector.
The host cell is characterized in that the host cell is selected from any one of pichia pastoris, saccharomyces cerevisiae, escherichia coli and bacillus subtilis.
Further, the application provides a method for preparing the recombinant ginseng hypoglycemic peptide, which is characterized by comprising the steps of encoding the recombinant ginseng hypoglycemic peptide, constructing an expression vector containing the recombinant ginseng hypoglycemic peptide gene, transferring the expression vector into a host cell, culturing the host cell transferred into the expression vector in a culture medium, and purifying polypeptide after induced expression to obtain the recombinant ginseng hypoglycemic peptide.
The method is characterized in that the purification method is selected from any one of salting out method, ultrafiltration method, affinity chromatography and gel filtration chromatography.
Further, the application provides application of the recombinant ginseng hypoglycemic peptide in preparation of a medicament for treating diabetes.
Further, the application provides application of the recombinant ginseng hypoglycemic peptide in preparation of medicaments for treating insulin resistance diseases.
Compared with the prior art, the application has the following advantages:
1. the recombinant ginseng hypoglycemic peptide of the application is obtained by repeating the natural ginseng hypoglycemic peptide for a certain times and then carrying out fermentation expression, thus being capable of effectively relieving the problem of easy degradation of short peptide.
2. Compared with the extraction of natural ginseng products, the recombinant ginseng hypoglycemic peptide can obtain higher yield, and compared with the extraction of natural products, the recombinant ginseng hypoglycemic peptide avoids the extraction operation of strong acid and strong alkali organic matters, and ensures the safety of products.
3. The recombinant ginseng hypoglycemic peptide prepared by the application is obtained by expression of escherichia coli, the expression yield is high, the target polypeptide can be obtained after one-step affinity purification, other redundant operations are not needed, and the purification efficiency can be effectively improved.
4. The recombinant ginseng hypoglycemic peptide prepared by the application is a small molecular polypeptide, and has the advantages of easy absorption, higher activity, smaller dosage and lower toxic and side effects.
5. The recombinant ginseng hypoglycemic peptide prepared by the application can effectively reduce blood sugar.
6. The recombinant ginseng hypoglycemic peptide prepared by the application can be added into health care products after simple treatment, and can be used as health care food.
The technical scheme of the application is further described in detail below with reference to the accompanying drawings and the examples.
Drawings
FIG. 1 shows pTYB11 original plasmid.
FIG. 2 is a recombinant plasmid of the ginseng hypoglycemic peptide pTYB11-ADGPRFT according to the embodiment 1 of the present application.
FIG. 3 is a diagram showing the electrophoresis of a target Gene (GSP) dextran gel according to example 1 of the present application.
FIG. 4 shows an electrophoresis pattern of protein expression in example 1 of the present application.
FIG. 5 is a Western Blotting-verifying protein expression electrophoresis pattern of example 1 of the present application.
FIG. 6 is a graph showing that recombinant ginseng hypoglycemic peptide according to example 4 promotes absorption of glucose by HepG2 cells.
FIG. 7 is a graph showing that the recombinant ginseng hypoglycemic peptide according to example 5 of the present application promotes the absorption of glucose by IR-HepG2 cells.
Detailed Description
The present application will now be described in detail with reference to the drawings and specific examples, which should not be construed as limiting the application. Unless otherwise indicated, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples are commercially available unless otherwise indicated.
The application repeats the natural ginseng hypoglycemic peptide for 2-15 times. The amino acid sequence of the natural ginseng hypoglycemic peptide is shown as SEQ ID NO. 1. In short, according to specific experimental requirements, the natural ginseng hypoglycemic peptide is connected end to end, for example, the natural ginseng hypoglycemic peptide is repeated 2 times, namely, the amino acid fragments shown in SEQ ID NO.1 are connected end to end, so that a 2-repeated amino acid fragment of ETVEIIDSEGGGDAETVEIIDSEGGGDA is formed. Other repetition times may be similarly used.
In a specific embodiment, the natural ginseng hypoglycemic peptide has the amino acid sequence shown as SEQ ID NO.2, wherein the repeated times of the natural ginseng hypoglycemic peptide are 4 times and the repeated times of the natural ginseng hypoglycemic peptide have the amino acid sequence shown as SEQ ID NO.2. The gene for coding the recombinant ginseng hypoglycemic peptide with the repetition number of 4 is subjected to codon optimization aiming at host cell expression, sac II and EcoR I restriction enzyme cutting sites are respectively added at two ends in the design process to facilitate later gene operation, the gene for coding the recombinant ginseng hypoglycemic peptide is obtained through the optimization, the nucleotide sequence of the gene is shown as SEQ ID NO.3, 1 st to 6 th are Sac II restriction endonuclease cutting sites, 7 th to 115 th original plasmid essential nucleotide sequences, 116 th to 283 th are nucleotide sequences corresponding to the natural ginseng hypoglycemic peptide repeated 4 times, 284 th to 286 th are terminators, and 287 nd to 292 th are EcoR I restriction endonuclease cutting sites. When other repetition numbers are involved, it is only necessary to replace positions 116 to 283 with the specifically required nucleotide sequence.
The present application provides an expression vector containing the gene, which may contain regulatory sequences such as transcription and translation initiation and termination codons, which are specific for the type of host (e.g., bacterial, fungal, plant or animal) to be introduced into the vector, and which take into account whether the vector is DNA-based or RNA-based, as appropriate.
In a specific embodiment, the expression vector is pTYB11, the plasmid map of which is shown in fig. 1.
The application also provides a host cell comprising the expression vector, which refers to a cell into which exogenous nucleic acid has been introduced, including the progeny of such a cell. Host cells include transformants and transformed cells, including primary transformed cells and progeny derived therefrom, regardless of the number of passages. The offspring may not be exactly identical in nucleic acid content to the parent cell but can contain mutations, and the host cell can be selected from any of Pichia pastoris, saccharomyces cerevisiae, E.coli, and B.subtilis.
In a specific embodiment, the host cell is E.coli BL21 (DE 3).
The application also provides a method for preparing the recombinant ginseng hypoglycemic peptide, which comprises the following steps: the host cell is used for expression, and then the expression is separated and purified to obtain the recombinant DNA. The expression of the host cell means that the host cell is cultured, and the culture medium and the culture conditions are well known to those skilled in the art.
In a specific embodiment, the host cell is escherichia coli, and specific culture conditions are as follows after obtaining escherichia coli genetically engineered bacteria: inoculating the escherichia coli genetic engineering bacteria into an LB (LB) culture medium, culturing for 16 hours at 37 ℃ and 220rpm, inoculating the seed solution into a 500mL shake flask according to 1% of inoculum size after expanding culture, wherein the culture temperature is 37 ℃, and adding IPTG (isopropyl-beta-D-thiogalactoside) for induction expression when the seed solution grows to a logarithmic growth phase, wherein the culture temperature is 25 ℃ and the culture time is 20 hours.
The expression pattern is not limited in any way, and the application can be confirmed as required, for example, the expression is induced expression, and the inducer is IPTG for the induced expression.
In a specific embodiment, IPTG is added for induction culture, the temperature of the induction stage is 25 ℃, bacterial liquid is centrifugally taken out to precipitate after 20 hours of induction, phosphate buffer solution is used for resuspension, and ultrasonic crushing is used.
The method for separation and purification is not limited in any way, and may be determined according to the implementation, and for example, salting out, ultrafiltration, affinity chromatography or gel filtration chromatography may be used.
Example 1: expression of recombinant ginseng hypoglycemic peptide
The application chemically synthesizes the recombined ginseng hypoglycemic peptide gene (the nucleotide sequence is shown as the 116 th-283 th positions of SEQ ID NO. 2). In the synthesis process, sac II and EcoR I recognition sites are respectively added at the 5 'end and the 3' end, the cloning is carried out to an expression vector pTYB11 (the nucleotide sequence is shown as SEQ ID NO.4, the plasmid map is shown as figure 2) after restriction enzyme Sac II and EcoR I are digested, and the obtained cloning plasmid is transformed into BL21 (DE 3) by a heat shock method by taking escherichia coli BL21 (DE 3) as an expression host bacterium. Coating the plates on LB solid plates added with ampicillin sodium, and inversely culturing overnight at 37 ℃ to obtain the escherichia coli genetic engineering bacteria.
Inoculating the obtained escherichia coli genetic engineering bacteria into an LB culture medium, inoculating the escherichia coli genetic engineering bacteria into a 500mL shake flask with an initial volume of 100mL according to an inoculum size of 1% when culturing for 16 hours, adding IPTG to perform induction culture when the culture temperature is 37 ℃ and OD600 = 0.6-0.8, performing induction at the induction stage temperature of 25 ℃ for 20 hours, and centrifugally collecting sediment. And carrying out ultrasonic disruption on the sediment, and carrying out protein expression condition verification. PCR, SDS-PAGE and Western Blotting assays are shown in FIGS. 3-5.
FIG. 3 shows the agarose gel electrophoresis of the target gene, PCR was performed on the recombinant plasmid, and a distinct band appears on the right side of the electrophoresis pattern, about 286bp, similar to the size of the target gene fragment.
FIG. 4 shows SDS-PAGE, and the recombinant ginseng hypoglycemic peptide with CBD-intein label has obvious band at about 60kD molecular weight in SDS-PAGE, and the molecular weight is matched with the expected molecular weight, and the successful expression of the target protein is verified.
FIG. 5 shows Western Blotting verification of CBD tag, and FIG. 5 shows that CBD tag is located at 60kD molecular weight, and the target protein is combined, so that the target protein is verified to be expressed successfully.
Example 2: purification of recombinant ginseng hypoglycemic peptide
(1) After the sediment centrifugally collected in the embodiment 1 is resuspended, the supernatant is ultrafiltered to 50 percent of the initial volume after ultrasonic crushing, 3 to 5 times of pure water is added, and then the mixture is ultrafiltered and concentrated to 5 percent of the initial volume;
(2) Taking a proper amount of filler for column packing, completely draining the protective liquid, and washing the balance column material with a Binding Buffer with 5 times of the volume for standby;
(3) Centrifuging the protein crushing liquid, taking supernatant, filtering by a 0.45 mu M filter membrane, adding the supernatant into the central position of the column, and slowly flowing through the column;
(4) Washing off unbound proteins with a Washing Buffer of 10 column volumes, and if necessary, collecting the flow-through for subsequent analysis;
(5) Then, the column is quickly washed by using a clear Buffer (30 mM-50 mM DTT is added before use) with 3 times of column volume, a sample outlet is closed, and the column is placed at 4 ℃ for 16-40 hours (the Cleavage reaction duration influences the Cleavage efficiency, so that the incubation time can be properly prolonged);
(6) Finally eluting the target protein fused with the intein-chitin binding domain by using an absorption Buffer with a volume of 3 times of the column volume;
(7) The chitin column should be cleared of intein-chitin binding domain fusion proteins and uncleaved proteins of interest after use;
(8) Cleaning procedure: washing the column with Stripping Solution with 3 times of column volume, soaking for 30 min-1 h, washing the resin with Stripping Solution with 7 times of column volume, washing the column with water with 20 times of column volume, and balancing the column with 20% ethanol solution with 5 times of column volume;
(9) Ultrafiltration and desalination; 25mL of G25 packing is adopted for desalting by a G25 desalting column, the operation process is similar to that of gel filtration chromatography, each time of loading 6.5mL, about 8mL is collected, and desalting can be completed after 10min of loading;
(10) Concentrating to 20-30% of the initial volume, pre-freezing in a refrigerator at-20deg.C for 4 hr, lyophilizing in a vacuum lyophilizing machine for 48 hr, collecting lyophilized protein, and storing the lyophilized protein sample in a refrigerator at-80deg.C for later use.
Note that:
Binding/Washing Buffer:20mM HEPES(pH8.0),500mM NaCl,0.1mM EDTA,0.1％～0.5％ Triton X-100；
cleavage Buffer, 20mM HEPES (pH 8.0), 500mM NaCl,0.1mM EDTA,50mM DTT (added before use);
Elution Buffer:20mM HEPES(pH8.0),500mM NaCl,0.1mM EDTA；
Stripping Solution:0.5M NaOH。
example 3 application of recombinant Ginseng hypoglycemic peptide in diabetes treatment drug
HepG2 cells were grown at 1X 10 4 The cells were inoculated into 96-well plates containing ginseng hypoglycemic peptide, and the effect of the cells on glucose absorption was examined, and a control group was set.
The following is a brief description: taking cells in logarithmic growth phase, digesting and centrifuging, washing with PBS for 3 times, treating with pancreatin containing EDTA, centrifuging, re-suspending, and diluting to final concentration of 1×10 5 mu.L of each well of cell suspension was added at 5% CO per mL 2 Incubated overnight at 37℃in an incubator, the original medium was aspirated, 100. Mu.L of MEM medium containing 20mM,40mM,80mM and 100mM of ginseng hypoglycemic peptide was added, 100. Mu.L of MEM medium containing 1mM of insulin was added to the control group, 6 wells were set for each concentration, and after culturing for 24 hours, the supernatant was centrifuged and the glucose content of each well was measured using a glucose oxidase test kit.
The calculation formula is as follows:
c standard: the concentration of the standard substance is 5.55mmol/L
The results of the promotion of glucose uptake by HepG2 cells by recombinant ginseng hypoglycemic peptide are shown in fig. 6. The result shows that the recombinant ginseng hypoglycemic peptide can obviously promote HepG2 cells to absorb glucose, the 40mM recombinant ginseng hypoglycemic peptide has the promotion effect equivalent to that of 1mM insulin, and the promotion effect is more obvious along with the increase of concentration.
Example 4 application of recombinant Ginseng hypoglycemic peptide in insulin resistance therapeutic drug
HepG2 cells were grown at 1X 10 4 The cells were inoculated into 96-well plates containing ginseng hypoglycemic peptide, and the effect of the cells on glucose absorption was examined, and a control group was set.
The following is a brief description: taking cells in logarithmic growth phase, digesting and centrifuging, washing with PBS for 3 times, treating with pancreatin containing EDTA, centrifuging, re-suspending, and diluting to final concentration of 1×10 5 Each mL, 100uL per well was added to the cell suspension at 5% CO 2 Incubation overnight at 37℃in incubator, aspiration of the original medium, first addition of MEM medium containing 18mM glucosamine for 16 hours, induction of insulin resistance in HepG2 cells, then aspiration of the medium, washing 2 times with PBS, addition of 100. Mu.L of MEM medium containing 20mM,40mM,80mM,100mM of ginseng hypoglycemic peptide, respectively, no insulin resistance induction in control group, cell culture with complete medium, 6 replicate wells at each concentration, centrifugation of supernatant after 24 hours, and detection of glucose content in each well using glucose oxidase test kit.
The calculation formula is as follows:
c standard: the concentration of the standard substance is 5.55mmol/L
The results of the promotion of glucose uptake by IR-HepG2 cells by recombinant ginseng hypoglycemic peptide are shown in FIG. 7. The result shows that the recombinant ginseng hypoglycemic peptide can obviously promote the IR-HepG2 cells to absorb glucose, and the promotion effect is more obvious along with the increase of the concentration.
Note P <0.05, P <0.01, P <0.001, compared to model set.
The foregoing description is only a preferred embodiment of the present application, and is not intended to limit the present application, and any simple modification, variation and equivalent structural changes of the above embodiment according to the technical matter of the present application still fall within the scope of the technical solution of the present application.
Claims (9)
1. A recombinant ginseng hypoglycemic peptide is characterized by being formed by repeating a short amino acid sequence of a natural ginseng hypoglycemic peptide as a repeating unit; the short amino acid sequence is ETVEIIDSEGGGDA (SEQ ID NO: 1), and the repetition number is 2-15.
2. A gene encoding the recombinant ginseng hypoglycemic peptide according to claim 1.
3. An expression vector comprising the gene of claim 2.
4. A host cell comprising the expression vector of claim 3.
5. The host cell of claim 4, wherein the host cell is selected from any one of Pichia pastoris, saccharomyces cerevisiae, E.coli and B.subtilis.
6. A method for preparing the recombinant ginseng hypoglycemic peptide according to claim 1, which is characterized by comprising the steps of constructing an expression vector containing the gene of the recombinant ginseng hypoglycemic peptide by encoding the gene of the recombinant ginseng hypoglycemic peptide, transferring the expression vector into a host cell, culturing the host cell transferred into the expression vector in a culture medium, and purifying the polypeptide after induced expression to obtain the recombinant ginseng hypoglycemic peptide.
7. The method according to claim 6, wherein the purification method is selected from any one of salting out method, ultrafiltration method, affinity chromatography method and gel filtration chromatography method.
8. Use of the recombinant ginseng hypoglycemic peptide according to claim 1 for preparing a medicament for treating diabetes.
9. Use of the recombinant ginseng hypoglycemic peptide according to claim 1 in the preparation of a medicament for treating insulin resistance diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311311882.9A CN117229381A (en) | 2023-10-10 | 2023-10-10 | Recombinant ginseng hypoglycemic peptide and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311311882.9A CN117229381A (en) | 2023-10-10 | 2023-10-10 | Recombinant ginseng hypoglycemic peptide and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117229381A true CN117229381A (en) | 2023-12-15 |
Family
ID=89084193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311311882.9A Pending CN117229381A (en) | 2023-10-10 | 2023-10-10 | Recombinant ginseng hypoglycemic peptide and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117229381A (en) |
-
2023
- 2023-10-10 CN CN202311311882.9A patent/CN117229381A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107245494B (en) | Efficient soluble expression and purification method of A β 42 in escherichia coli | |
| WO2024087761A1 (en) | Method for producing polypeptide from recombinant fusion protein and use thereof | |
| CN111423486A (en) | Renaturation method of new type coronavirus recombinant protein inclusion body | |
| CN113025675B (en) | Process for producing polypeptide | |
| WO2023045682A1 (en) | Method for increasing soluble expression quantity of polypeptide | |
| JP2019048807A (en) | Novel method of protein purification | |
| CN113025598A (en) | Method for preparing recombinant heparinase III by utilizing SUMO fusion expression system and SUMO _ heparinase III fusion protein prepared by method | |
| TWI660042B (en) | Expression construct and method for producing proteins of interest | |
| CN114657113A (en) | Recombinant bacterium for expressing totipotent nuclease and application thereof | |
| CN111499759B (en) | Zinc finger protein-lactoferrin fusion protein with cell membrane penetrating property and preparation and application thereof | |
| CN112480227B (en) | Protein for improving pathogenic bacterium resistance of sturgeon and preparation method and application thereof | |
| CN116554309A (en) | Recombinant human III type collagen and preparation method and application thereof | |
| CN117229381A (en) | Recombinant ginseng hypoglycemic peptide and preparation method and application thereof | |
| CN102277371A (en) | Method for preparing BNP (brain natriuretic peptide) | |
| CN112646044B (en) | TFF2-Fc fusion protein and high-efficiency expression production method thereof | |
| CN113249288B9 (en) | Recombinant bacterium for expressing GLP-1 analogue and application thereof | |
| CN107746432A (en) | A kind of modified proteins of A β 42 and its expression and purification method | |
| CN113980880A (en) | Genetically engineered bacterium, application thereof and method for producing psicose by taking glucose as raw material | |
| CN111606987A (en) | Application of glistening protein as fusion label, recombinant protein and expression method thereof | |
| CN111116757A (en) | Ferritin fusion protein with galactose-binding lectin EW29 label, protein cage nanoparticles and preparation method thereof | |
| CN114644715B (en) | Preparation method of fusion protein and complex of IGFBP-3 and IGF-1 | |
| CN110079542B (en) | Recombinant expression method and application of hypoglycemic peptide Aglycin | |
| CN112941058B (en) | Recombinant clostridium histolyticum type II collagenase as well as preparation method and application thereof | |
| CN117143223B (en) | Preparation method of biological synthetic human body structural material | |
| CN112322616B (en) | Expression and purification method of UDP-glucose-4-epimerase from hericium erinaceus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |